What four episodes of The Genetics Podcast reveal about the future of Alzheimer’s precision medicine
Alzheimer’s research is entering a new phase. For decades, the field has been shaped by the biology of amyloid plaques and tau tangles. Those remain central to ...
Continue reading
In the most recent episode of The Genetics Podcast, Patrick Short speaks with Dr. Sarah Marzi, Senior Lecturer at King’s College London and Group Leader at the ...
Continue reading
Precision medicine sponsors invest heavily to identify, educate, screen, consent, genotype, and support rare patients. In many programs, once a trial ends, that...
Continue reading
UK Biobank and similar resources have made an extraordinary contribution to biomedical research, enabling important advances across genomics, population health,...
Continue reading
Recruitment in precision medicine and rare disease trials remains constrained by fragmented data, low prevalence populations, and heavy reliance on site-based p...
Continue reading
On the latest episode of The Genetics Podcast, Patrick Short speaks with Dr. Suzanne Schindler associate professor of neurology at Washington University in St. ...
Continue reading
Rare disease exposes the limits of current clinical development models. Small, fragmented populations make patient identification difficult. Heterogeneous biolo...
Continue reading
Rare disease drug development involves decision-making under extreme uncertainty. Teams are asked to design trials without well-established endpoints, in small ...
Continue reading
Liver disease remains one of the few major disease areas where outcomes have not improved in line with other fields such as cardiovascular disease and cancer. I...
Continue reading
In rare disease and genetically stratified trials, recruitment often depends on a single critical step: confirming that a patient carries the relevant genetic v...
Continue reading